All In Biotech

Drug Trial Radar · NCT06806657

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE ≥ 12 Years of Age

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Apr 28, 2025

Primary completion

Jun 29, 2026

Study completion Jun 29, 2026

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Feb 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.

Conditions

  • Hereditary Angioedema

Interventions

  • GaradacimabBiological

    Participants will receive a loading dose of garadacimab, followed by once monthly garadacimab administration for 2 months. Garadacimab will be given as a subcutaneous injection. The timing for the administration of the loading dose (first administration of garadacimab) is determined by the dosing schedule of the current HAE prophylactic treatment. No washout necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 95 (End of study [EoS])
  2. Percentage of Participants With TEAEsTime frame: Up to Day 95 (EoS)
  3. Number of TEAEsTime frame: Up to Day 95 (EoS)
  4. Rate of TEAEs per injectionTime frame: Up to Day 95 (EoS)
  5. Rate of TEAEs per participant yearTime frame: Up to Day 95 (EoS)

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Solutions of Arizona

    Litchfield Park, Arizona

  • Allergy and Asthma Clinic of Northwest Arkansas

    Bentonville, Arkansas

  • Donald Levy M.D.

    Orange, California

  • Raffi Tachdjian MD, Inc.

    Santa Monica, California

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Chronicle Bio

    West Valley City, Utah

  • Clinique Spécialisée en Allergie de la Capitale

    Québec, Canada

  • McMaster University-Hamilton

    Hamilton, Ontario, Canada

  • Montreal Clinical Research Institute

    Montreal, Quebec, Canada

  • HZRM Hämophilie Zentrum Rhein Main GmbH

    Frankfurt, Germany

  • Hautklinik und Poliklinik der Universitätsklinik Mainz

    Mainz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.